Search form

Boehringer Ingelheim and CANbridge started collaboration on CAN017 development and manufacturing in 2016

CANbridge reached important next milestone for cancer antibody

Boehringer Ingelheim BioChina is fully committed to and prepared for late stage and commercial supplies globally

Shanghai, China, August 20, 2018 - CANbridge Life Sciences, a biotech company privately-held and headquartered in Beijing, China, announced that it has received Clinical Trial Application (CTA) approval from the China Food and Drug Administration (CFDA) to conduct clinical trials in China with its drug candidate CAN017.

Boehringer Ingelheim’s biopharmaceutical contract manufacturing business, known as Boehringer Ingelheim BioXcellence™, is providing the Chemistry, Manufacturing, and Control (CMC) services for CAN017 since the collaboration started in August 2016. Boehringer Ingelheim BioChina supported the successful application approval by GMP compliant manufacturing and support for China CTA regulatory filing services from CMC perspective.

CAN017 is an ErbB3 (HER3) inhibitory antibody for the treatment of esophageal squamous cell cancer (ESCC). ESCC is the most prevalent form of esophageal cancer and occurs primarily in Asia with 50% cases in China. CANbridge acquired the development rights of CAN017 from US-based AVEO in 2016 after the completion of US Phase 1 trial in solid tumors and will now commence Phase Ib/III study in China.

Dr. Jiali Luo, General Manager and Site Head of Boehringer Ingelheim BioChina, congratulates CANbridge for the progress achieved with CAN017: “Through our supplies at the highest global quality standards, we are committed to providing CANbridge with full support to commercialization. We are proud of being CANbridge’s partner to serve cancer patients with this important medicine”.

About Boehringer Ingelheim Biopharmaceuticals China
As one of the world’s largest biopharmaceutical producers, Boehringer Ingelheim is China’s first international provider of biopharmaceutical contract manufacturing solutions with all-round services, including process development, clinical trials and product supply, to its clients in China and all over the world. Boehringer Ingelheim China Biopharmaceuticals Site was officially put into operation in May 2017. As the first and only biopharmaceuticals site in line with global standards set by a multinational pharma company in China, the site has become a major milestone in Boehringer Ingelheim’s strategic blueprint for its biopharmaceuticals business globally.

Boehringer Ingelheim
Improving the health and quality of life of patients is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2017, Boehringer Ingelheim achieved net sales of nearly 18.1 billion euros. R&D expenditure, exceeding three billion euros, corresponded to 17.0 per cent of net sales.

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.

Intended audiences:
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.